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1. Abstract 
The aim of this work was the formulation and comparison of different drug carrier systems for the transdermal 
delivery of lidocaine. Quality target product profile and quality attributes were identified, and an initial risk 
assessment was made according to the Quality by Design methodology. The critical quality attributes influencing 
the quality and efficacy of the final drug formulation were then defined in order to select the control points and 
proper methods for measurements. Four formulation types, each containing 5 % lidocaine were compared: 
conventional hydrogel, oleogel, lyotropic liquid crystal and nanostructured lipid carrier. Microscopic analysis, 
particle size and zeta potential measurements, Fourier transform infrared spectroscopy and Raman spectroscopy 
were performed to characterize the critical parameters in case of the different vehicles. Membrane diffusion and 
penetration studies were completed as well for each formulation in vitro and ex vivo, followed by measurements 
on skin hydration and transepidermal water loss in vivo. Our results lead us to the conclusion that the 
nanostructured lipid carrier is the most promising vehicle for the topical delivery of lidocaine. It showed the best 
penetration properties through heat separated epidermis and the highest moisturizing effect which are the most 
critical parameters based on the Quality by Design initial risk assessment and evaluation. 
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2. Introduction 
Semisolid systems are the most usual formulations for the delivery of drugs through the skin. Topically applied 
anesthetics are employed in order to eliminate the pain caused by needle insertion and injection, thus ameliorating 
patient compliance. Furthermore, they are devoid of the symptoms of superficial trauma and local reaction (i.e. 
erythema, venous sequelae, nerve damage) [1].  
However, most of the marketed topical formulations have moderate skin penetration properties, rapid but short 
effect, thus the development of local topical anesthetics with a release in a prolonged fashion at the site of action 
is desperately desired [2]. Therefore, this work was undertaken to develop and compare a new formulation of 
lidocaine (LID), proposed to improve its clinical effectiveness in topical anesthesia in terms of both enhanced 
anesthesia and a prolonged duration of action.  
For the goal that has been set, the penetration of lidocaine into the dermal layer is required. The sustained 
release of the drug is desired in order to improve patient compliance during long term treatments [3]. To satisfy 
the requirements of industrial and regulatory aspects, long term stability and appropriate dosage strength are also 
essential. 
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For this purpose, we investigated new topical drug delivery systems, such as lyotropic liquid crystals (LLC) 
and nanostructured lipid carriers (NLC), which can provide the above-mentioned increased duration of local 
action [4]. We incorporated LID as a free base into oleogel, LLC and NLC, and compared it with the LID 
hydrochloride containing hydrogel as a control. Hydrogel and oleogel are conventional drug carrier systems with 
a simpler structure than NLC and LLC. The marketed formulations contain LID hydrochloride in various 
concentrations (1-5 %, w/w) incorporated in ointment, gel, and solution [5]. The ionized form of LID can penetrate 
more rapidly than the free base but it is quickly absorbed and cleared off by the cutaneous capillaries [6].  
LLC systems are becoming increasingly widespread because of their ability to be excellent drug carriers since 
they have a unique, skin-similarly structure and attractive physicochemical properties as they show a structure 
typical of fluids and the crystalline state of solids as well. They form gel-like phases with special internal 
structures, into which drugs can be loaded [7]. Their preparation is cost effective and easy as they are usually 
formed with low energy input from water and one or two surfactants and possibly cosurfactants in the definitive 
amounts of the components. Further advantages of these systems include easy storage, thermodynamic stability, 
sustained drug release, and similarity to colloid systems in living organisms. LLC systems with a lamellar structure 
demonstrate the greatest similarity to the intercellular lipid membrane of the skin, so they are primarily 
recommended for the development of a dermal dosage form [8].  
Drug release from lyotropic liquid crystals depends on the percent ratio of water or water-surfactant in the 
lamellar liquid crystals, the presence of the totally lipophilic components, and the dissociation of the drug. A 
previous study revealed that the lidocaine base is able to diffuse freely through the liquid crystalline system, while 
the diffusion of the hydrochloride salt is delayed because this from is entrapped within the water layers of the 
lamellae [9].  
New approaches in topical local anesthetic treatments include the use of the eutectic mixture of the local 
anesthetics (EMLA) lidocaine and prilocaine and the application of liposomal lidocaine, which has several 
advantages, like a faster onset of action and fewer adverse effects. This liposomal formulation is available under 
the trade names Maxilene 4 (RGR Pharma, Windsor, Ontario) and LMX (formerly ELA-Max; Ferndale 
Laboratories, Ferndale, Michigan) [10]. 
It has been shown that the incorporation of lidocaine into liposomes results in higher effectiveness, making 
shorter application periods as well as a decrease in side effects possible [6]. However, NLCs are modern 
alternatives of liposomes with many advantages, such as better physical stability, low cost (no need of expensive 
phospholipids), possibility of scale-up and manufacturing, potential in epidermal targeting, follicular delivery, 
controlled drug delivery and photostability improvement of active pharmaceutical ingredients [5].  
NLCs are the second generation of lipid nanoparticles wherein solid lipid is partially substituted by liquid 
lipids. This structure allows the drug to be located in the liquid lipid, which predicts the better mobility of the 
drug, therefore improved stability and controlled drug release [11]. Additionally, the similarity of NLC forming 
lipids to physiological molecules makes these systems well tolerated, biodegradable and non-toxic. The 
interaction of the lipid nanoparticles with the skin lipids and sebum is dependent on the hydrophobicity of the 
incorporated molecule, the location of the drug within the formulation (incorporated into a lipid matrix or on the 
surface) and the type of the interacting skin lipid [12]. Furthermore, lipid particles, when the particle size is less 
than 200 nm, form a thin layer on the skin surface, reducing the transepidermal water loss and increasing the 
hydration, thereby they facilitate the penetration of the incorporated drug and support the physiological conditions 
of the skin [13–16]. Previous work proved that lidocaine NLC formulation can provide 2.5 h deep local anesthesia, 
and the total duration of anesthesia was up to 6 h, while the application of the conventional gel provided only 1 h 
of total anesthesia [5]. Other in vitro release studies showed reduced permeation through the skin, which could be 
related to a high reservoir capacity of the stratum corneum, due to the interaction between the lipid components 
of NLCs and the SC lipid matrix [17–20]. To develop formulations suitable for dermal application, NLC was 
incorporated in a hydrogel-based system.  
Quality by Design (QbD) in pharmaceutics is a systematic, scientific, risk-based, holistic and proactive method 
that begins with determining objectives and puts emphasis on understanding product and processes control [21–
23]. In the development of new pharmaceutical formulations, the application of QbD approach results in a fast 
and improved optimization process by determining the quality target product profile (QTPP) and the critical 
quality attributes (CQAs) [24–27] Risk assessment is carried out to identify the potential hazards and parameters 
which possibly affect product quality [28]. We applied some initial elements of this method to effectively choose 
the best formulation regarding the target of this work (Figure 1). 
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Fig 1. Flow chart of Quality by Design approach in formulation development. 
 
3. Materials and methods 
3.1 Materials 
Lidocaine, Lidocaine hydrochloride and Macrogol 400 were obtained from Hungaropharma Ltd. (Budapest, 
Hungary). Aerosil® 200 was purchased from Sigma-Aldrich (Budapest, Hungary). Cremophor® RH 40 (PEG-40 
Hydrogenated Castor Oil; HLB value: 14–16) and Cremophor® RH 60 (PEG-60 Hydrogenated Castor Oil; HLB 
value: 15–17) were kindly supplied by BASF SE Chemtrade GmbH (Ludwigshafen, Germany). Miglyol® 812 N 
(caprylic/capric triglyceride) was a gift by Sasol GmbH (Hamburg, Germany). Isopropyl myristate (IPM) was 
purchased from Merck Kft. (Budapest, Hungary), Methocel™ K4M (hydroxypropyl methylcellulose) was from 
Colorcon (Budapest, Hungary) and Apifil® (PEG-8 Beeswax) was a gift from Gattefossé (St. Priest, France). The 
water used was puriﬁed and deionized with the Milli-Q system (Millipore, Milford, MA, USA). 
3.2 Quality by design methodology 
3.2.1 Definition of the QTPP and CQAs 
The first step of the product development based on the QbD approach is the definition of the target product 
profile (TPP), which includes the definition of the dosage form, route of administration, dosage strength, etc. 
QTPPs are determined to ensure the quality, safety and efficacy of the product, and general elements of a QTPP 
for a dermal formulation are: site of activity, dosage form, release profile, etc. depending on the therapeutic aim. 
The second step is to define the quality attributes of the formulation, namely to determine physicochemical 
and biological properties or characteristics that should be within the defined limit or distribution to ensure the 
desired product quality. These attributes determine the performance of the formulation, they are originated from 
the QTPP and they take prior knowledge as a basis. The CQAs are usually defined properties, like physical 
attributes, viscosity, homogeneity of the semisolid dosage form [29].  
3.2.2 Initial risk assessment: risk analysis of CQAs 
A combination of the probability of occurrence of risk and severity of the risk is defined as risk assessment 
according to ICH Q9 quality risk management [28]. Performing this step before the development of a product can 
help the researcher to decide which studies need to be conducted. With the help of this method, critical and non-
critical variables can be defined to establish a control strategy for in process and final testing. We evaluated the 
risks using an Ishikawa diagram. The risk estimation matrix (REM) presents the interdependence rating between 
QTPPs and CQAs. Based on the REM data, a Pareto chart can be designed, which shows the greatest chance of 
affecting the final quality of the product, and can be employed to assign the critical attributes which should be 
investigated during the development process. The screening of the parameters and the definition of the critical 
control points were carried out by the LeanQbD™ software (QbD Works LLC, Fremont, CA, USA). The Ishikawa 
diagram was constructed to identify the effect of key material attributes and process parameters for the optimized 
development of semisolid systems (Figure 2). 
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Fig. 2. Ishikawa diagram 
Notes: Conc. refers to “concentration” 
3.3 Sample preparation 
3.3.1 Conventional hydrogel 
The conventional hydrogel was prepared from 5 % (w/w) lidocaine hydrochloride dissolved in the mixture of 
purified water, ethanol and macrogol 400, and 3 % (w/w) Methocel K4M was added to this solution as the gelling 
agent. 
3.3.2 Oleogel 
To formulate the oleogel, Mygliol 812 N and Cremophor® RH 40 (as a penetration enhancer) mixture was 
heated (60 °C) and 5 % (w/w) lidocaine base was dissolved in this mixture. 5 % (w/w) Aerosil 200 was added to 
prepare gels. 
3.3.3 Lyotropic liquid crystal  
Samples produced with oil-surfactant (IPM: Cremophor® RH40= 1:4) mixture were heated (60 °C) and 
homogenized with a magnetic stirrer, 5 % (w/w) lidocaine base was dissolved and 10 % (w/w) of water was then 
added to the lipid phase in small amounts under stirring.  
3.3.4 Nanostructured lipid carrier 
The solid lipid was melted at 80 °C, and Mygliol 812 N and lidocaine were added under moderate stirring. 
Under the same conditions, the water phase was prepared with surfactant (Cremophor® RH60) and HPLC water. 
Then the water phase was added to the lipid phase and put under high shear homogenizer for 1 minute (8000 rpm). 
The obtained pre-emulsion was ultrasonified using a Hielscher UP200S compact ultrasonic homogenizer 
(Hielscher Ultrasonics GmbH, Germany) for one cycle, 70 % amplitude, 10 min. In the end, the sample was cooled 
down in ice bath to get the NLC dispersion. Then, a gel was formed (at room temperature) with glycerin and 
Methocel K4M and the NLC dispersion was added to reach a final 5 % (w/w) lidocaine concentration. 
3.4 Characterization of the carrier systems 
3.4.1 Microscopic analysis of LLC 
The LLC samples were investigated under polarized light microscopy in order to study the texture of the 
lamellar phases. A small quantity of the sample was placed on a clean glass slide and observed under crossed 
polars using a magnification of 200×.  
3.4.2 Particle size and zeta potential of NLC 
The average particle size (PS, z-average size) and zeta potential (ZP) of the NLC formulation were determined 
by dynamic light scattering with a Zetasizer Nano ZS device (Malvern Instruments, UK). The measurement 
medium was purified water with a refractive index of 1.33. The sample was thermostated to 25 °C and 
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measurements were made in disposable folded capillary cells. Each measurement was done in triplicate. To 
calculate the ZP from the electrophoretic mobility, the Helmholtz-Smoluchowski equation was applied.  
Zeta potential below |30| mV is considered to be stable, but many studies demonstrated that not only 
electrostatic repulsion influences the stability of nanoparticles but the use of a steric stabilizer (like Cremophor® 
RH 60 in this formulation) also supports the formation of a stable nanoparticle dispersion [30]. 
3.4.3 Fourier transform infrared spectroscopy analysis of NLC 
The Fourier transform infrared spectroscopy (FT-IR) spectra of the NLC were recorded with an Avatar 330 
FT-IR spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) equipped with a horizontal ATR crystal 
(ZnSe, 45°), between 4000 and 400 cm−1, with 128 scan, at an optical resolution of 4 cm−1. For the spectral 
analysis Thermo Scientific GRAMS/AI Suite software (Thermo Fisher Scientific Inc., Waltham, MA, USA) was 
used. 
3.4.4 Raman spectroscopy measurements of NLC 
The Raman spectra of the NLC was acquired with a Thermo Fisher DXR Dispersive Raman Spectrometer 
(Thermo Fisher Scientific Inc., Waltham, MA, USA) equipped with a CCD camera and a diode laser operating at 
532 nm. The spectra of the NLC components, lidocaine-free and LID-NLC samples were with an exposure time 
of 6 s, with 24 scans, including cosmic ray and fluorescence corrections. Measurements were carried out with a 
laser power of 10 mW at a slit width of 25 μm. 
3.5  Drug diffusion and penetration investigations 
3.5.1 Preparation of heat-separated epidermis 
Excised human skin was obtained from a Caucasian female patient who underwent abdominal plastic surgery, 
with the approval of the Ethical Committee of the University of Szeged, Albert Szent-Györgyi Clinical Centre 
(Human Investigation Review Board license number: 83/2008.). For the separation of epidermis, the heat 
separation technique  was applied [31]. The obtained epidermal membrane was applied onto the surface of PBS 
(phosphate buffer solution, pH = 7.4) for at least 20 min and then set on a supporting mixed cellulose ester 
membrane (Porafil, Machenerey-Nagel, Düren, Germany, and Pall Life Sciences, Washington, NY, USA; pore 
diameter 0.45 μm) for the measurements. 
3.5.2 Franz diffusion cell method 
In vitro and ex vivo permeation of LID was measured using a vertical Franz diffusion cell system (Hanson 
Research, Chatsworth, CA, USA) in a six-unit assembly (effective permeation area 1.676 cm2) for 24 h at 
37±0.5 °C. The donor phase was 0.30-0.40 g of the appropriate formulation, which was placed on a mixed 
cellulose ester membrane (Porafil, Machenerey-Nagel, Düren, Germany, and Pall Life Sciences, Washington, NY, 
USA) itself (in vitro), or in the case of ex vivo measurements the epidermis was supported with a Porafil membrane 
filter. Phosphate buffer saline (PBS) pH 7.4 was used as the acceptor medium and it was stirred at 450 rpm 
throughout the experiment. At selected time intervals, samples of 0.8 mL were taken from the acceptor phase by 
the autosampler (Hanson Research, Chatsworth, CA, USA) and replaced with an equal volume of fresh receiver 
medium. The amount of permeated drug was measured using a Unicam Heλios Thermospectronic UV–VIS 
spectrophotometer (Unicam, Thermo Fisher Scientific Inc., Waltham, MA, USA) at 262 nm. Five parallel 
measurements were carried out and the amount of LID penetrating during a time period was plotted. The results 
were expressed as means ± SD for the evaluation of drug release kinetics. 
3.5.3 Penetration analysis 
The in vitro and ex vivo penetration of LID was calculated in terms of the mean cumulative amount permeated 
through the membrane, taking the diffusion area into account. The results were plotted as a function of time. The 
steady state flux (J) was calculated from the slope of the linear regression versus t1/2 and expressed in μg cm−2 h−1. 
3.6 Measurement of skin hydration and transepidermal water loss 
3-4-month-old male SKH-1 hairless mice were employed to evaluate the effect of LID-free formulations on 
skin hydration and transepidermal water loss. The mice were kept in a thermoneutral environment with a 12 h 
light–dark cycle in plastic cages and they had access to standard laboratory chow and water ad libitum. All 
experiments were in full accordance with the NIH guidelines and the interventions were approved by the Ethical 
Committee for the Protection of Animals in Scientific Research at the University of Szeged (license number: 
V./145/2013). Prior to the treatments, the animals were anesthetized with a mixture of ketamine 
(90 mg/kg bodyweight) and xylazine (25 mg/kg bodyweight), administered intraperitoneally. At the end of the 
experiments, the mice were euthanized with an overdose of ketamine (300 mg/kg). 
For the treatment, 0.2 g of each formulation was deposited on the dorsal skin surface of hairless mice, left for 
30 minutes for penetration, and after the diffusion period the skin surface was cleaned with a dry cotton swab. 
Skin hydration was measured using a Corneometer CM 825 (Courage und Khazaka, Germany) and TEWL 
was evaluated with Tewameter TM 300, both connected to a Multi Probe Adapter MPA 5 (Courage und Khazaka, 
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Germany), 30, 90 and 150 minutes after the application. The results are given in percentage compared to the levels 
before treatment. 
3.7 Statistical analysis 
The results were analysed statistically with the two-way ANOVA analysis of variance (Bonferroni post-test) 
using Prism for Windows software (GraphPad Software Inc., La Jolla, CA, USA). Differences were regarded as 
significant if p< 0.05*, p<0.01** and p< 0.001*** versus the control. 
4. Results and discussion 
4.1 Definition of QTPP and CQAs 
We aimed to develop a semisolid local anesthetic formulation for dermal use, which can provide effective and 
prolonged anesthesia. This therapeutic efficacy of the formulations depends on therapeutic indication, route of 
administration, site of activity, dosage form, release profile, stability and dosage strength. The CQAs are derived 
from the QTPPs. The quality attributes are identified as physical attributes, solubility of API in drug product, 
homogeneity of API in drug product, in vitro drug release, ex vivo drug release, moisturizing effect, TEWL, dosage 
form type and viscosity. Table 1 presents the list of QTPP and CQA parameters with their targets and 
justifications. 
Table 1 
QTPP and CQAs of the target local anesthetic formulation 
QTTP parameters Target Justification 
Therapeutic indication local anesthetic Local anesthesia and pain alleviating are required in various minor 
surface-skin surgical conditions and invasive procedures. Local 
anesthetics are also available to provide temporary relief from 
pain, irritation and itching caused by various conditions. 
Route of administration Dermal The dermal delivery of drugs is an opportunity to avoid systemic 
side effects and the hepatic metabolism of drugs, thus the 
application of lower doses is available. Furthermore, it is a non-
invasive, easy-to-use method resulting in high patient compliance.  
Site of activity Topical The topical activity of local anesthetic drugs is desired because of 
their systematic side effects. Topical formulations are designed to 
allow the dermal penetration of their actives into the deeper 
regions of the skin, such as the viable epidermis and the dermis, 
where the nerve fibers are located. The absorption into the 
systemic circulation is not the aim of these formulations. 
Dosage form Semisolid system Semisolid systems offer many advantages, like easy application 
and pleasing rheological behavior, which enable them to adhere to 
the application surface and they are able to topically deliver many 
drug molecules. 
Release profile Sustained drug 
release 
Prolonged duration local anesthesia is desirable to effectively treat 
pain and to reduce the number of applications, thus improving 
patient compliance. 
Stability (physical, 
chemical, biological) 
no visible sign of 
instability at the time 
of preparation and 
after 1 months (at 
room temperature) 
It is essential to maintain the physical, chemical and biological 
stability of the product over time because stability issues, like 
phase separation, change in pH, viscosity, appearance and crystal 
formation can affect the release and therapeutic effect of the 
formulation. 
Dosage strength 5g/100g 5% lidocaine formulations are effective as local, topical anesthetic 
preparations.  
CQA Target Justification 
Physical attributes (color, 
odor, appearance) 
Clear, translucent or 
opaque appearance, 
and odorless smell 
Physical attributes are not critical, but satisfactory appearance can 
improve patient compliance. However, they are not directly in 
connection with safety and efficiency. 
Solubility of API in drug 
product 
High (>90 %) Drug solubility provides uniformity of dosage form by preventing 
phase separation. Furthermore, a high concentration gradient can 
increase the diffusion force across the skin.  
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4.2 Initial risk assessment 
In this study, the initial risk assessment plan identified the critical quality attributes of product quality 
expectation. The risk estimation matrix presents the interdependence rating between the QAs and QTPPs on the 
three-level scale (Table 2). For the probability rating a 1 (low)-3 (medium)-9 (high) scale was used, considering 
all CQAs and their relationship to the QTTPs. The following properties were found to influence product quality: 
in vitro and ex vivo drug release (both 18 %), dosage from type (15 %), moisturizing effect and TEWL (both 
13 %). Based on the REM results, a Pareto chart (Figure 3) was generated showing the severity scores of CQAs, 
which lead us to the following findings: in vitro and ex vivo drug release, dosage from type, moisturizing effect 
and TEWL with the highest severity score (>300), suggesting that these are the most critical characteristics 
influencing the quality of the formulation. The Pareto chart illustrates the critical attributes which have to be 
considered during the development process. Based on the results of the risk assessment, these points have been 
investigated in this research. 
Table 2 
Selected QTPPs and CMAs representing their interdependence rating with risk estimation matrix (Lean-QbD Software): 
Low = low risk parameter; Medium = medium risk parameter; High= high risk parameter. 
 
Dosage 
form (H) 
Route of 
administra-
tion (H) 
Site of 
activity (H) 
Therapeutic 
indication 
(H) 
Release 
profile (H) 
Stability 
(M) 
Dosage 
strength (M) 
Physical 
attributes 
2% Low Low Low Low Low Low Low 
Solubility of 
API 
10% High Low Low Medium High Low High 
Homogeneity 
of API in drug 
product 
7% Medium Low Low Medium High Medium Medium 
In vitro drug 
release 
18% High High High High High Medium High 
Ex vivo drug 
release 
18% High High High High High Medium High 
Moisturizing 
effect 
13% High High Medium High Medium Low Low 
TEWL 13% High High Medium High Medium Low Low 
Viscosity 4% Medium Low Low Low Medium Medium Low 
Dosage form 
type 
15% High High Medium High High Medium Medium 
Homogeneity of API in 
drug product 
Homogenous 
distribution of the 
API 
Homogeneity is crucial to provide the uniformity of dosage units 
during the application period. 
In vitro drug release Sustained 
(compared to 
control) 
Slow drug release is required to provide prolonged anesthesia. 
Ex vivo drug release Sustained 
(compared to 
control) 
Slow drug release is required to provide prolonged anesthesia.  
Permeability is less through human skin than synthetic membrane 
based on preliminary results in the literature. 
Moisturizing effect Increase of basal 
skin hydration 
(compared to 
control) 
An increase of the water content of the skin promotes drug 
permeation. 
TEWL Minor and transient 
change in TEWL 
values (compared to 
control) 
A high value of transepidermal water loss is related to the 
disruption of the barrier function of the skin. 
Viscosity Optimal 
spreadability of the 
product 
(range: 1000-
50000 mPas) 
Rheological properties, such as the viscosity of semisolid dosage 
forms, can influence their drug delivery. Viscosity may directly 
influence the diffusion rate of drug at the microstructural level. 
Dosage form type Penetration 
enhancing properties 
The composition and the special structure of the vehicle can 
ameliorate the penetration of active agents.  
CQAs 
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Fig. 3. Pareto analysis of the identified CQAs. 
4.3 Polarization Microscopic Examinations 
Figure 4 presents a polarized microscopic picture of the developed blank and lidocaine containing LLC structures, 
revealing a lamellar LLC pattern with a characteristic „Maltese cross” structure in polarized light [32]. Liquid 
crystals are anisotropic materials and they display characteristic textures between crossed polarizers under an 
optical microscope. These textures can be used to identify different liquid crystalline phases. Liquid crystals are 
visible by polarizing light microscopy as lipid circular droplets with characteristic birefringence in the shape of a 
Maltese cross. The presence of the Maltese cross indicates a parallel orientation of one of the main axes of the 
structure in the plane of polarization of the incident light, so linearly polarized light passing through will not 
change its polarization, resulting in dark regions [33].  
 
Fig. 4. Polarizing microscopic examination of blank (A) and lidocaine containing (B) LLC. 
4.4 Results of particle size and zeta potential analysis 
The particle size of the NLC system was 87.61±0.55 nm. The calculated polydispersity index was 
0.1615±0.01, referring to a monodisperse distribution [34,35]. The low polydispersity index predicts a satisfying 
stability of the system [13]. The zeta potential was -11.983±0.31 mV.  
4.5 FTIR and Raman analysis of NLC 
For the determination of API-excipient interactions in the NLC formulation at the level of functional groups, 
we applied FT-IR and Raman spectroscopy. In order to evaluate chemical interaction among LID and the carriers, 
FT-IR and Raman spectra of Apifil®, Miglyol® 812 N, Cremophor® RH60, LID, LID-free NLC and LID-NLC 
formulations were studied as shown in Figure 5. The characteristic bands are presented in Table 3 with the 
vibrational assignments (cm-1) [36]. 
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Fig. 5. FT-IR (A) and Raman (B) spectra of individual components and NLC compositions. 
Notes: Apifil (1), Cremophor® RH60 (2), Mygliol 812 N (3), Lidocaine (4), Lidocaine-free NLC (5), Lidocaine NLC (6) 
 
Table 3 
Observed FT-IR and Raman peaks (in cm-1) and peak assignments for lidocaine 
Observed peaksa  
Infrared Raman Assignment 
 3043 (m) methyl antisymmetric stretching 
2970 (s) 2973 (m) methyl antisymmetric stretching 
 2922 (vs) CH2 antisymmetric and symmetric stretching 
2874 (s) 2875 (m) methyl symmetric stretching 
2800 (m)  CH2 symmetric stretching 
1664 (vs) 1664 (w) C=O stretching 
1593 (m) 1594 (vs) HNC scissor deformation, NC amide stretching 
1497 (vs)  methyl antisymmetric deformation 
 1484 (m) methyl antisymmetric deformation 
 1452 (vs) CH2 scissor deformation 
1421 (s)  methyl symmetric deformation 
1385 (m)  CH2 wag 
 1375 (m) CH2 twist, CH2 wag 
1338 (w)  ring stretching deformation III, CH2 twist, CH2 wag 
1292 (s)  CH2 twist 
 1264 (vs) m-CH bend, o-CC symmetric stretching 
1207 (s) 1215 (m) amide NH stretching, CC stretching 
1167 (s) 1164 (m) NC2 antisymmetric stretching, CH2 rock, CH2 twist 
1121 (s)  m-CH bend, ring stretching deformation II 
 1094 (s) methyl rock, CH2 twist 
1074 (vs) 1075 (w) methyl rock 
1036 (s) 1037 (vw) methyl rock 
987 (m) 991 (m) CH2 rock, CH wag 
 972 (w) CH wag 
 959 (w) CC stretching, NCO scissor deformation 
918 (w) 909 (vw) CC stretching 
 877 (w) ring bend deformation, ring N-stretching 
818 (m)  CH3 rock 
764 (vs)  CH wag 
 754 (w) ring torsional deformation, HNC wag 
704 (s) 705 (vs) HNC wag 
 661 (m) ring stretching deformation,  
615 (s) 616 (vvs) NCO wag 
521 (m) 512 (vw) ring torsional deformation II 
488 (s) 486 (w) ring bend deformation II 
 232 (s) o-CC wag 
a Intensity abbreviations: vw: very weak, w: weak, m: medium, s: strong, vs: very strong, vvs: very very strong. 
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The intense band in the FT-IR spectrum of LID observed at 2970 cm-1 is associated mostly with the methyl 
group antisymmetric stretching mode. The intense band at 1664 cm-1 is assigned to C=O stretching band. The 
very strong intensity 1497 cm-1 peak is composed mostly of mixed methyl and methylene deformations. A strong 
line is observed at 1296 cm-1, corresponding to the twisting of all methylene groups in the molecule.  group of 
strong and very strong intensity lines observed at 1207, 1167, 1121, 1074, and 1037 cm-1 is calculated to have a 
high degree of mixing (N–C, C–C stretches, ring bending deformation I and II, N–C2 antisymmetric stretch, 
methylene rock and twist, methyl group rocking). The next lower group of intense bands in the IR spectrum begins 
with a very strong line at 764 cm-1 and consists of CH wags and ring torsional deformation.  
In the Raman spectra, LID exhibited characteristic peaks at 2922, 1594, 1452, 1264, 1094 and 705 cm-1. At 
2922 cm-1 there is a very intense line in the spectrum, which is calculated to be highly mixed from methylene CH2 
stretching in the two ethyl groups. In the Raman spectrum the peak at 1594 cm-1 corresponds to HNC scissoring 
and NC stretching modes. The peak at 1452 cm-1 is mostly due to methylene scissoring. At 1263 cm-1 a very 
intense line is observed, corresponding mainly to CH bending and C–C symmetric stretching modes. The strong 
peak at 1094 cm-1 is attributed to methyl rock, CH2 twist and NC2 symmetric stretch. At about 705 cm-1 there 
appears a very strong peak in the Raman spectrum consisting of HNC wag and twist and of ring torsional 
deformation.  
The 1497 cm-1 peak, related to the methyl functional groups of LID, is present in the FTIR spectra of LID-
NLC, but absent from the spectra of the blank NLC, indicating the presence of LID in the lipid nanoparticle. As 
all the characteristic peaks of the drug and the excipients were present in the LID-NLC spectrum and no shifting 
of existing peaks or creation of new peaks were observable, this indicates that there were only physical interactions 
among the drug and the excipients, and no chemical interaction took place among them. The Raman measurements 
confirmed these results: the peaks at 616, 705, 1264, 1594 cm-1, which are the characteristic features of the LID 
spectra, are present in the LID-NLC spectra without shifting, and missing from the blank NLC. The absence of 
chemical interactions between the drug and the vehicle suggests that the release of lidocaine from the carrier 
system is not inhibited. 
5. Result of in vitro release and ex vivo permeation studies 
In Figure 6, the plots of the cumulative amounts of LID permeated through artificial mixed cellulose ester 
membrane (A) and human heat separated epidermis (B) as a function of time are shown. Drug flux values for 
formulations are reported in Table 4.  
The in vitro diffusion of LID through the artificial membrane from the different formulations is illustrated in 
Figure 6A. The LLC formulation showed a complete release of LID at the end of 15-18 h. The conventional 
hydrogel exhibited a fast onset of permeation, but the permeation was not completed after 24 h (78.58±2.50 %). 
The oleogel and NLC formulations provided a sustained release, 70.32 %±1.76% of the drug was released from 
the oleogel, 58.66 %±4.28 from NLC after 24 h. 
Ex vivo penetration patterns were slightly different, presumably because of the interaction of the different 
vehicles and the skin lipids and proteins (Figure 6B). LID permeation from the oleogel exhibited the lowest value, 
only 9.84±1.37 % of the drug penetrated after 24 h. There was no significant difference between the penetration 
of conventional hydrogel (15.05 %±3.70) and LLC (14.12 %±1.73) formulation. Surprisingly, through the 
epidermis, the NLC formulation exhibited the most complete penetration (19.44 %±5.05), whereas in vitro it was 
the lowest. This finding could be explained by the special structure of the NLC, which allows the high 
bioavailability of this formulation [2]. The components of the NLC formulation have similar lipophilicity as the 
skin, so they have good miscibility with the skin lipids, and this can cause greater penetration [37]. Our results 
are in good agreement with other studies, which revealed that lipid nanocarriers can improve penetration and 
effectiveness of encapsulated lidocaine [2,5,38,39]. The high penetration rate of LID through the epidermis 
predicts the fast accumulation of the drug in the dermis, which is the site of action for local anesthetics. Babaei et 
al. confirmed that NLC can penetrate through the epidermis and accumulate in the dermal layers of the skin [40]. 
The low permeation rates of oleogel could be explained by their composition: they do not contain any water (in 
contrast to the other formulations), so there will be no external supply of water, hydration can only be provided 
from the internal processes of the skin [41].  
Table 4 
Steady-state fluxes of LID in vitro and ex vivo from different formulations 
 Flux (μg cm-2 h-1) 
 in vitro ex vivo 
Conventional hydrogel 2175.59 369.23 
Oleogel 1844.57 259.66 
LLC 3211.42 373.99 
NLC 1682.02 618.05 
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Fig. 6. In vitro (A) and ex vivo (B) diffusion studies of LID containing formulations. 
p< 0.05*, p<0.01** and p < 0.001*** 
6. Skin hydration and TEWL measurements 
In skin hydration measurements (Figure 7A), there were no significant differences between the hydrating effect 
of conventional hydrogel and LLC. Both of them increased the hydration slightly after 30 minutes (13.63±5.23 % 
and 18.42±3.12 %), and this effect was shortened after 150 minutes (6.92±5.88 % and 11.78±3.95 %). However, 
oleogel caused a dramatic decrease of hydration after 30 minutes (-43.47±5.93 %). This could be the result of the 
presence of Cremophor® RH40 in the formulation, which is a well-known penetration enhancer that disturbs the 
ordered lipid structure of the stratum corneum, resulting in the loss of water content [42]. Furthermore, in the 
oleogel formulation, there was no water as an excipient, so after the application there is no chance to supply the 
lost water from this source. After 150 minutes, the skin barrier seemed to have recovered partly, and the hydration 
value (-27.57±6.03 %) was closer to the initial level. NLC resulted in a remarkable increase in skin hydration after 
30 minutes (71.18±3.31 %) and the hydration maintained a high level also after 150 minutes (64.65±5.46 %).  
The TEWL changes displayed notable differences between the effects of formulations (Figure 7B). NLC 
caused the slightest increase in TEWL (14.68±3.19 % after 30 minutes, 18.46±2.45 % after 90 minutes and 
22.78±7.39 % after 150 minutes). It is well-known that lipid nanostructures with a particle size less than 200 nm 
form a lipid film on the skin surface, and owing to this occlusive effect, the TEWL changes will decrease, thus 
hydration will increase[43]. Our results confirmed these findings and are in good agreement with the ex vivo 
penetrations studies, because improved skin hydration and occlusion are shown to increase drug absorption from 
topical formulations [44]. 
Conventional hydrogel caused a slightly noticeable TEWL increase after 30 minutes (36.20±11.25 %), but this 
effect was reduced after 150 minutes (19.71±5.71 %). However, oleogel increased TEWL significantly 
(51.24±6.66 % after 30 minutes,67.33±9.06 % after 90 minutes and 67.73±3.54 % after 150 minutes), which can 
explain the dramatic decrease in hydration values discussed earlier. The TEWL rise was the most significant for 
LLC. The increase was 101.39±4.24 % after 30 minutes, and it still rose after 150 minutes to 130.08±7.95 %. The 
reason for this huge water loss is definitely the high amount of surfactant (Cremophor® RH40) incorporated in the 
LLC formulation. However, skin hydration was not negatively affected because of the lamellar, water-containing 
structure of the LLC, which can provide excellent hydration and compensate for the high TEWL values [45].  
 
Fig. 7. Skin hydration (A) and transepidermal water loss (B) changes after exposure to formulations. 
Values are given as percentage referring to values before treatments vs. conventional hydrogel. 
p< 0.05*, p<0.01** and p < 0.001*** 
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7. Conclusion 
The selection of an adequate drug carrier system with proper material attributes for transdermal delivery is 
fundamental to reach the aim of application. In this work we compared the properties, skin penetration and 
hydrating effect of different formulations for the delivery of lidocaine by applying the QbD concept during the 
development process, which revealed the critical points that should be investigated.  
The oleogel represented low penetration rates, both in vitro and ex vivo, and caused a negative effect on skin 
hydration. LLC showed a high release of the drug in vitro, and moderate flux values ex vivo, however, this 
formulation increased TEWL dramatically. The penetration of the NLC formulation was the most significant 
through heat separated epidermis after 24 hours, and the skin hydrating and occlusive effect makes it a favorable 
carrier system. 
These findings suggest the use of novel nanostructured drug carrier systems for transdermal drug delivery, 
though further investigations are needed to completely understand the penetration profiles of these carrier systems, 
and to define the crucial factors affecting the drug release and diffusion. For the further development of the chosen 
system, critical material attributes (CMA) and critical process parameters (CPP) should be defined and 
comprehensive risk assessment steps are needed to be performed to understand the parameters that produce the 
final product with the required characteristics. 
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